Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a serious liver disorder associated with the accumulation of fat and inflammation. The objective of this study was to determine the gut microbiota composition that might influence the progression of NAFLD. Germ-free mice were inoculated with feces from patients with nonalcoholic steatohepatitis (NASH) or from healthy persons (HL) and then fed a standard diet (STD) or high-fat diet (HFD). We found that the epididymal fat weight, hepatic steatosis, multifocal necrosis, and inflammatory cell infiltration significantly increased in the NASH-HFD group. These findings were consistent with markedly elevated serum levels of alanine transaminase, aspartate transaminase, endotoxin, interleukin 6 (IL-6), monocyte chemotactic protein 1 (Mcp1), and hepatic triglycerides. In addition, the mRNA expression levels of Toll-like receptor 2 (Tlr2), Toll-like receptor 4 (Tlr4), tumor necrosis factor alpha (Tnf-α), Mcp1, and peroxisome proliferator-activated receptor gamma (Ppar-γ) significantly increased. Only abundant lipid accumulation and a few inflammatory reactions were observed in group HL-HFD. Relative abundance of Bacteroidetes and Firmicutes shifted in the HFD-fed mice. Furthermore, the relative abundance of Streptococcaceae was the highest in group NASH-HFD. Nevertheless, obesity-related Lactobacillaceae were significantly upregulated in HL-HFD mice. Our results revealed that the gut microbiota from NASH Patients aggravated hepatic steatosis and inflammation. These findings might partially explain the NAFLD progress distinctly was related to different compositions of gut microbiota.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To establish causality, transplantation of fecal microbiota from patients with MASLD or MASH induced steatosis and fibrosis in antibiotic-treated and germ-free mice (87, 202, 203).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [203]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gut Microbiota Is a Key Modulator of Insulin Resistance in TLR 2 Knockout Mice
Caricilli, A. M., Picardi, P. K., de Abreu, L. L., Ueno, M., Prada, P. O., Ropelle, E. R., Hirabara, S. M., Castoldi, Â., Vieira, P., Camara, N. O. S., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001212 · Cited by 282
RetractedAn obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444 · cited 2×
“Hence, colonization of GF mice with the “obesity-related microbiota” resulted in a significant increase in total body fat relative to GF mice colonized with a “thinness-related microbiota” [22].”
BackgroundThe gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 1×
“In one study, Backhed and coworkers reported that the colonization of GF mice with microbiota from conventionally raised animals produces an increase in body fat [25].”
BackgroundObesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176 · cited 1×
“Research has shown that the relative abundance of Bacteroidetes is lower and that of Firmicutes is higher in obese mice compared to their leaner counterparts [26].”
BackgroundGut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788 · cited 1×
“Follow-up experiments involving human fecal samples from twins discordant for obesity (when transplanted into gnotobiotic mice) showed significant body composition differences [15].”
The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice
Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000322 · Cited by 3,058 · cited 3×
“The level of Bacteroidetes is significantly lower in obese subjects as compared with normal-weight subjects [13].”
BackgroundThe Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Cited by
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688
Walter, J., Armet, A. M., Finlay, B. B., & Shanahan, F. (2020) · Cell · doi:10.1016/j.cell.2019.12.025 · Cited by 596
The role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523
Chu, H., Duan, Y., Yang, L., & Schnabl, B. (2019) · Gut · doi:10.1136/gutjnl-2018-316307 · Cited by 354
Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications
Chen, J., & Vitetta, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155214 · Cited by 352
The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases
An, L., Wirth, U., Koch, D., Schirren, M., Drefs, M., Koliogiannis, D., Nieß, H., Andrassy, J., Guba, M., Bazhin, A. V., et al. (2022) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-021-05188-7 · Cited by 284
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron-Wisnewsky, J., Warmbrunn, M. V., Nieuwdorp, M., & Clément, K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.049 · Cited by 239
Dey, P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104367 · Cited by 209
Fei, N., Bruneau, A., Zhang, X., Wang, R., Wang, J., Rabot, S., Gérard, P., & Zhao, L. (2020) · mBio · doi:10.1128/mbio.03263-19 · Cited by 168
Role of gut microbiota via the gut-liver-brain axis in digestive diseases
Ding, J.-H., Jin, Z., Yang, X.-X., Lou, J., Shan, W.-X., Hu, Y.-X., Du, Q., Liao, Q.-S., Xie, R., & Xu, J.-Y. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i40.6141 · Cited by 168
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
Liver–Microbiome Axis in Health and Disease
Adolph, T. E., Grander, C., Moschen, A. R., & Tilg, H. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.002 · Cited by 150
Ji, Y. S., Yin, Y., Sun, L., & Zhang, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093066 · Cited by 140
Khan, A., Ding, Z., Ishaq, M. H., Bacha, A. S., KHAN, I. A., Hanif, A., Li, W., & Guo, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.56214 · Cited by 140
Promises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Meng, X., Li, S., Li, Y., Gan, R.-Y., & Li, H.-B. (2018) · Nutrients · doi:10.3390/nu10101457 · Cited by 115
Self-citationDrożdż, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J., & Lip, G. Y. H. (2021) · Nutrients · doi:10.3390/nu14010103 · Cited by 122
Tokuhara, D. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.700058 · Cited by 112
Choi, W. J., Dong, H. J., Jeong, H. U., Ryu, D. W., Song, S. M., Kim, Y. R., Jung, H. H., Kim, T. H., & Kim, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-57615-5 · Cited by 109
Interactions between Host PPARs and Gut Microbiota in Health and Disease
Hasan, A. U., Rahman, A., & Kobori, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020387 · Cited by 101
Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases
Bruneau, A., Hundertmark, J., Guillot, A., & Tacke, F. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.725390 · Cited by 88
Kobayashi, T., Iwaki, M., Nakajima, A., Nogami, A., & Yoneda, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911689 · Cited by 100
Geographic Differences in Gut Microbiota Composition Impact Susceptibility to Enteric Infection
Porras, A. M., Shi, Q., Zhou, H., Callahan, R., Montenegro-Bethancourt, G., Solomons, N., & Brito, I. L. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109457 · Cited by 74
Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
Malnick, S. D. H., Alin, P., Somin, M., & Neuman, M. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416226 · Cited by 92
Maestri, M., Santopaolo, F., Pompili, M., Gasbarrini, A., & Ponziani, F. R. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1110536 · Cited by 79
Zeng, H., Larson, K., Cheng, W., Bukowski, M. R., Safratowich, B. D., Liu, Z., & Hakkak, R. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108336 · Cited by 80
Peiseler, M., & Tacke, F. (2021) · Cancers · doi:10.3390/cancers13040730 · Cited by 71
Burz, S. D., Monnoye, M., Philippe, C., Farin, W., Ratziu, V., Strozzi, F., Paillarse, J.-M., Chêne, L., Blottière, H. M., & Gérard, P. (2021) · Microorganisms · doi:10.3390/microorganisms9010199 · Cited by 69
Circulating microbiota-derived metabolites: a “liquid biopsy?
Aragonès, G., Colom-Pellicer, M., Aguilar, C., Guiu-Jurado, E., Martínez, S., Sabench, F., Antonio Porras, J., Riesco, D., Del Castillo, D., Richart, C., et al. (2020) · International Journal of Obesity · doi:10.1038/s41366-019-0430-0 · Cited by 69
Intestinal microbiome as a novel therapeutic target for local and systemic inflammation
Uchiyama, K., Naito, Y., & Takagi, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.006 · Cited by 72
Chen, Y., Chiu, C.-C., Hung, S., Huang, W.-C., Lee, Y.-P., Liu, J.-Y., Huang, Y.-T., Chen, T.-H., & Chuang, H.-L. (2019) · Nutrition Research · doi:10.1016/j.nutres.2019.07.001 · Cited by 60
Self-citationLanthier, N., Rodriguez, J., Nachit, M., Hiel, S., Tréfois, P., Neyrinck, A. M., Cani, P. D., Bindels, L. B., Thissen, J., & Delzenne, N. M. (2021) · Scientific Reports · doi:10.1038/s41598-020-79718-9 · Cited by 71
Seth, R. K., Kimono, D., Alhasson, F., Sarkar, S., Albadrani, M., Lasley, S. K., Horner, R., Janulewicz, P., Nagarkatti, M., Nagarkatti, P., et al. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.006 · Cited by 55
“These changes in the liver have been associated with an altered microbiome following consumption of a diet rich in high fat and low fiber for a long period of time at least in the murine models (Chiu et al., 2017; Marra & Svegliati-Baroni, 2018).”
InfluentialZhou, D., Zhang, J., Xiao, C., Mo, C., & Ding, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964477 · Cited by 68
Lin, W., Yue, F., Lin, X., Wu, S., Shi, Y., Li, J., Xiang, X., Lam, S. M., Shui, G., Russell, R., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01975 · Cited by 64
Mbaye, B., Borentain, P., Wasfy, R. M., Alou, M. T., Armstrong, N., Mottola, G., Meddeb, L., Ranque, S., Gerolami, R., Million, M., et al. (2022) · Cells · doi:10.3390/cells11213390 · Cited by 51
Auguet, T., Bertran, L., Binetti, J., Aguilar, C., Martínez, S., Sabench, F., Lopez-Dupla, J. M., Porras, J. A., Riesco, D., Castillo, D. D., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114189 · Cited by 62
Crosstalk between PPARs and gut microbiota in NAFLD
Wu, L., Li, J., Feng, J., Ji, J., Yu, Q., Li, Y., Zheng, Y., Dai, W., Wu, J., & Guo, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111255 · Cited by 53
Self-citationMarroncini, G., Naldi, L., Martinelli, S., & Amedei, A. (2024) · Biomedicines · doi:10.3390/biomedicines12071398 · Cited by 60
Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease
Steensels, S., Qiao, J., & Ersoy, B. A. (2020) · Metabolites · doi:10.3390/metabo10070283 · Cited by 58
He, B., Jiang, J., Shi, Z., Wu, L., Yan, J., Chen, Z., Luo, M., Cui, D., Xu, S., Yan, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111183 · Cited by 52
MASLD development: From molecular pathogenesis toward therapeutic strategies
Yang, Z., Zhao, J., Xie, K., Tang, C., Gan, C., & Gao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003629 · Cited by 58
Adapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease
Hundertmark, J., Krenkel, O., & Tacke, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02418 · Cited by 44
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease
Nawrot, M., Peschard, S., Lestavel, S., & Staels, B. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154844 · Cited by 51
Lechner, S., Yee, M. F., Limketkai, B. N., & Pham, E. A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06100-0 · Cited by 44
Xu, Q., Zhang, J., Lu, Y., & Wu, L. Y. (2024) · iScience · doi:10.1016/j.isci.2024.108783 · Cited by 50
Gómez‐Zorita, S., Aguirre, L., Milton‐Laskibar, I., Fernández‐Quintela, A., Trepiana, J., Kajarabille, N., Mosqueda-Solís, A., González, M. A., & Portillo, M. P. (2019) · Nutrients · doi:10.3390/nu11092156 · Cited by 40
Soundharrajan, I., Kuppusamy, P., Srigopalram, S., Lee, J. C., Sivanesan, R., Kim, D., & Choi, K. C. (2020) · The FASEB Journal · doi:10.1096/fj.202000971r · Cited by 46
Gut microbiome as a therapeutic target for liver diseases
Singh, T. P., Kadyan, S., Devi, H., Park, G., & Nagpal, R. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121685 · Cited by 44
Gao, Y., & Tian, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411811 · Cited by 43
Microbiota and nonalcoholic fatty liver disease: promising prospects for clinical interventions?
Knudsen, C., Neyrinck, A. M., Lanthier, N., & Delzenne, N. M. (2019) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000584 · Cited by 42
Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
Ткач, С. М., Dorofeyev, A., Kuzenko, I., Boyko, N., Falalyeyeva, T. M., Boccuto, L., Scarpellini, E., Kobyliak, N. M., & Abenavoli, L. (2022) · Medicina · doi:10.3390/medicina58010084 · Cited by 41
Tsai, H., Shih, Y.-Y., Yeh, Y., Huang, C., Liao, C., Hu, C., Nagabhushanam, K., Ho, C., & Chen, Y. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c00641 · Cited by 40
Mohammed, S. K., Magdy, Y., El-Waseef, D. A. E.-D. A., Nabih, E. S., Hamouda, M. A., & El-Kharashi, O. A. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.112762 · Cited by 41
Angelini, G., Castagneto‐Gissey, L., Salinari, S., BERTUZZI, A., Anello, D., Pradhan, M., Zschätzsch, M., Ritter, P., le Roux, C. W., Rubino, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35310-5 · Cited by 41
Outside the liver box: The gut microbiota as pivotal modulator of liver diseases
Wahlstrom, A. M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.07.004 · Cited by 37
Wang, M., Zhang, Y., Miller, D., Rehman, N., Cheng, X., Yeo, J., Joe, B., & Hill, J. W. (2020) · Endocrinology · doi:10.1210/endocr/bqz041 · Cited by 40
Key genes associated with non-alcoholic fatty liver disease and acute myocardial infarction
Dai, W., Sun, Y., Jiang, Z., Du, K., Xia, N., & Zhong, G. (2020) · Medical Science Monitor · doi:10.12659/msm.922492 · Cited by 40
Jiménez-González, C., Alonso‐Peña, M., Vélez, P. A., Crespo, J., & Iruzubieta, P. (2025) · Nutrients · doi:10.3390/nu17091580 · Cited by 46
Ge, M., Niu, W., Ren, J., Cai, S., Yu, D., Liu, H., Zhang, N., Zhang, Y., Wang, Y., Shao, R., et al. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0195-3 · Cited by 38
The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD
Huang, W., & Kong, D. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111235 · Cited by 41
Self-citationAge-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention
Campagnoli, L. I. M., Marchesi, N., Vairetti, M., Pascale, A., Ferrigno, A., & Barbieri, A. (2022) · Cells · doi:10.3390/cells11182827 · Cited by 37
Interplay Between Drug-Induced Liver Injury and Gut Microbiota: A Comprehensive Overview
Li, G., Hou, Y., Zhang, C., Zhou, X., Bao, F., Yang, Y. H., Chen, L., & Yu, D. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.05.003 · Cited by 40
Approaches to discern if microbiome associations reflect causation in metabolic and immune disorders
Basic, M., Dardevet, D. P., Abuja, P. M., Bolsega, S., Bornes, S., Caesar, R., Calabrese, F. M., Collino, M., Angelis, M. D., Gérard, P., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2107386 · Cited by 36
Zhang, Y., Jiang, W., Xu, J., Wu, N., Wang, Y., Lin, T., Liu, Y., & Liu, Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.535940 · Cited by 33
Alemán, J. O., Henderson, W. A., Walker, J. M., Ronning, A., Jones, D. R., Walter, P. J., Daniel, S. G., Bittinger, K. L., VAUGHAN, R. D., MacArthur, R. B., et al. (2021) · Journal of Clinical and Translational Science · doi:10.1017/cts.2021.801 · Cited by 40
Bahitham, W., Banoun, Y., Aljahdali, M., Almuaiqly, G., Bahshwan, S. M., Aljahdali, L., Sanai, F. M., Rosado, A. S., & Sergi, C. M. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1637071 · Cited by 41
Nishiyama, M., Ohtake, N., Kaneko, A., Tsuchiya, N., Imamura, S., Iizuka, S., Ishizawa, S., Nishi, A., Yamamoto, M., Taketomi, A., et al. (2020) · Nutrients · doi:10.3390/nu12030839 · Cited by 35
Ghosh, S., Yang, X., Wang, L., Zhang, C., & Zhao, L. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.011 · Cited by 38
Tang, R., Liu, R., Zha, H., Cheng, Y., Ling, Z., & Li, L. (2023) · Engineering in Life Sciences · doi:10.1002/elsc.202300016 · Cited by 32
Esmail, M., Anwar, S., Kandeil, M., Elzanaty, A. M., & Abdel‐Gabbar, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111818 · Cited by 27
Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis
Zhu, W., Zhou, Y., Tsao, R., Dong, H., & Zhang, H. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.861854 · Cited by 38
Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease
Bellanti, F., Buglio, A. L., & Vendemiale, G. (2023) · Metabolites · doi:10.3390/metabo13030322 · Cited by 29
Colaci, C., Gambardella, M. L., Scarlata, G. G. M., Boccuto, L., Colica, C., Luzza, F., Scarpellini, E., Méndez‐Sánchez, N., & Abenavoli, L. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2023.134 · Cited by 27
Qian, L., Gao, R., Huang, J., & Qin, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7801 · Cited by 29
Microbiome−mediated crosstalk between T2DM and MASLD: a translational review focused on function
Jing, M., & Jiang, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1677175 · Cited by 24
Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis
Dornas, W., & Lagente, V. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.026 · Cited by 25
Dissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
Colella, F., Henderson, N. C., & Ramachandran, P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186421 · Cited by 31
Tang, W., Yuan, M., Li, Z., Lin, Q., Zhen, Y., Zhuang, L., Zhou, H., & Xia, F. (2022) · Nutrients · doi:10.3390/nu14224930 · Cited by 22
The Pan-liver Network Theory: From Traditional Chinese Medicine to Western Medicine
Zhang, Y., & Fang, X.-M. (2023) · The Chinese Journal of Physiology · doi:10.4103/cjop.cjop-d-22-00131 · Cited by 30
Perazza, F., Leoni, L., Selvatici, B., Girolami, F., Bonalumi, A., Beretta, A., Ferri, S., Petroni, M. L., Piscaglia, F., Ravaioli, F., et al. (2025) · Nutrients · doi:10.3390/nu17111906 · Cited by 26
A pilot study to examine the association between human gut microbiota and the host's central obesity
Koo, S. H., Chu, C. W., Khoo, J. J. C., Cheong, M., Soon, G. H., Ho, E. X. P., Law, N. M., de Sessions, P. F., Fock, K. M., Ang, T. L., et al. (2019) · JGH Open · doi:10.1002/jgh3.12184 · Cited by 21
Meng, W., Zhao, Z., Chen, L., Lin, S., Zhang, Y., He, J., Ouyang, K., & Wang, W. (2022) · Foods · doi:10.3390/foods11142169 · Cited by 23
Targeting the Adipose Tissue–Liver–Gut Microbiota Crosstalk to Cure MASLD
Gabbia, D., & Martin, S. D. (2023) · Biology · doi:10.3390/biology12121471 · Cited by 25
Ramos, L. F., da Silva, C. M., Pansa, C. C., & Moraes, K. C. M. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1820321 · Cited by 20
Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease
Jin, L.-T., & Xu, M.-Z. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1113643 · Cited by 19
Human Gut Microbiota in Cardiovascular Disease
Ronen, D., Rokach, Y., Abedat, S., Qadan, A., Daana, S., Amir, O., & Asleh, R. (2024) · Comprehensive physiology · doi:10.1002/cphy.c230012 · Cited by 33
Human microbiota-associated animal models: a review
Huang, X., Yu, Y., Tian, N., Huang, J., Zhang, X., & Yu, R. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1644187 · Cited by 21
Cai, C., Chen, D., Ge, L.-C., Chen, W., Ye, S.-S., Ye, W., Tao, Y., Wang, R., Li, J., Lin, Z., et al. (2019) · PubMed · Cited by 21
Yang, S., Chen, Y.-H., Hu, J., Chiu, C., Hung, S.-W., Chang, Y.-C., Chiu, C.-C., & Chuang, H.-L. (2021) · Biology · doi:10.3390/biology10080737 · Cited by 20
Self-citationGut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics
Pandey, H., Goel, P., Srinivasan, V. M., Tang, D. W. T., Wong, S. H., & Lal, D. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i6.106849 · Cited by 23
Chen, Y.-H., Wang, Y., Chiu, C.-C., Lee, Y.-P., Hung, S.-W., Huang, C., Chiu, C., Chen, T.-H., Huang, W.-C., & Chuang, H.-L. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108362 · Cited by 15
Self-citationMicrobiota reprogramming for treatment of alcohol-related liver disease
Siddiqui, M. T., & Cresci, G. (2020) · Translational research · doi:10.1016/j.trsl.2020.07.004 · Cited by 16
Huang, Y., Zhang, Y., Wu, K., Tan, X., Lan, T., & Wang, G. (2024) · Molecules · doi:10.3390/molecules29112663 · Cited by 16
Self-citationDietary patterns interfere with gut microbiota to combat obesity
Lou, X., Li, P., Luo, X., Lei, Z., Liu, X., Liu, Y., Gao, L., Xu, W., & Liu, X. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1387394 · Cited by 21
Of Mice and Men and Nonalcoholic Steatohepatitis
Brenner, D. A. (2018) · Hepatology · doi:10.1002/hep.30186 · Cited by 13
“In particular, fecal microbiota transplants from patients with NAFLD will confer the NASH phenotype to gnotobiotic mice on a western diet as compared to fecal transplants from matched donors without NASH (6).”
Zhu, M., Cheng, Y., Tang, Y., Li, S., Rao, P., Zhang, G., Xiao, L., & Liu, J. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1271835 · Cited by 19
Self-citationProbiotics maintain the gut microbiome homeostasis during Indian Antarctic expedition by ship
Srivastava, A. K., Rohil, V., Bhushan, B., Eslavath, M. R., Gupta, H., Chanda, S., Kumar, B., Varshney, R. K., & Ganju, L. (2021) · Scientific Reports · doi:10.1038/s41598-021-97890-4 · Cited by 30
Luo, Z., Yang, L., He, J., Han, Y., Rong, X., Luo, D., & Guo, J. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105640 · Cited by 12
Metadata
- Authors
- Chiu, C.-C., Ching, Y.-H., Li, Y.-P., Liu, J.-Y., Huang, Y.-T., Huang, Y.-W., Yang, S.-S., Huang, W.-C., & Chuang, H.-L.
- Affiliations
- Agricultural Technology Research Institute (TW)
- Tzu Chi University (TW)
- National Chung Hsing University (TW)
- National Institutes of Applied Research (TW)
- Cathay General Hospital (TW)
- National Taipei University of Nursing and Health Science (TW)
- Corresponding author
- Huang, Wen-Ching
- Chuang, Hsiao-Li
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2017-11-06
- Volume
- 9
- Issue
- 11
- Pages
- 1220
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC5707692
- OpenAlex
- W2765713881
- Cited by
- 160
- References
- 59
- Citations by year
- 2026: 5 · 2025: 18 · 2024: 18 · 2023: 24 · 2022: 21 · 2021: 22 · 2020: 27 · 2019: 15 · 2018: 10
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology (MOST) of Taiwan (MOST 106-2319-B-492-001, NSC 100-2320-B-492-001-, NSC 101-2320-B-492-001-MY3, MOST 106-2410-H-227-007-)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, gut microbiota, high-fat diet, gnotobiotic mice, fecal microbiota transplantation, hepatic steatosis, liver inflammation, Toll-like receptors, Bacteroidetes, Firmicutes, Streptococcaceae, Lactobacillaceae, endotoxin, interleukin-6, MCP-1, TNF-α, PPARγ
- MeSH terms
- Gastrointestinal Microbiome, Adipose Tissue, Animals, Germ-Free Life, Humans, Liver, Male, Mice, Inbred C57BL, Mice, Diet, High-Fat, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.